11/20
11:50 am
aim
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board
Medium
Report
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board
11/19
08:08 am
aim
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer [Yahoo! Finance]
High
Report
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer [Yahoo! Finance]
11/19
08:00 am
aim
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
High
Report
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
11/19
07:06 am
aim
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board [Yahoo! Finance]
High
Report
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board [Yahoo! Finance]
11/19
07:00 am
aim
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board
High
Report
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board
11/18
12:45 pm
aim
Roswell Park Clinical Trial Points Toward Promising New Therapy for Most Aggressive Type of Breast Cancer
Low
Report
Roswell Park Clinical Trial Points Toward Promising New Therapy for Most Aggressive Type of Breast Cancer
11/16
02:13 am
aim
AIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]
Low
Report
AIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]
11/15
07:41 am
aim
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/15
07:29 am
aim
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
High
Report
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/15
07:07 am
aim
AIM ImmunoTech GAAP EPS of -$0.06 [Seeking Alpha]
High
Report
AIM ImmunoTech GAAP EPS of -$0.06 [Seeking Alpha]
11/14
09:08 am
aim
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board [Yahoo! Finance]
Medium
Report
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board [Yahoo! Finance]
11/14
09:00 am
aim
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board
Medium
Report
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board
11/6
09:00 am
aim
AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast
Medium
Report
AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast
11/4
08:00 am
aim
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
Medium
Report
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
10/22
05:38 pm
aim
AIM ImmunoTech Inc. (NYSE: AIM) had its price target lowered by analysts at Maxim Group from $2.00 to $1.00. They now have a "buy" rating on the stock.
Low
Report
AIM ImmunoTech Inc. (NYSE: AIM) had its price target lowered by analysts at Maxim Group from $2.00 to $1.00. They now have a "buy" rating on the stock.
10/9
09:00 am
aim
AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
Low
Report
AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
10/3
08:45 am
aim
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
High
Report
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
9/30
09:00 am
aim
AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
Medium
Report
AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
9/27
08:00 am
aim
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
Low
Report
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
9/19
08:00 am
aim
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
High
Report
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
9/11
09:00 am
aim
AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
Medium
Report
AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
9/3
08:04 am
aim
AIM ImmunoTech Inc. (NYSE: AIM) had its price target lowered by analysts at Ascendiant Capital Markets from $5.25 to $5.00. They now have a "buy" rating on the stock.
Low
Report
AIM ImmunoTech Inc. (NYSE: AIM) had its price target lowered by analysts at Ascendiant Capital Markets from $5.25 to $5.00. They now have a "buy" rating on the stock.